The U.S. Food and Drug Administration is working at “lightning speed” to review data on Gilead Sciences Inc’s experimental antiviral drug remdesivir in treating COVID-19 disease, the head of the agency told Bloomberg in an interview.
US FDA moving with ‘lightning speed’ on Gilead’s COVID-19 drug – Bloomberg
